Bengaluru: Biocon Biologics Ltd, a subsidiary of Biocon Ltd, has entered into a settlement and license agreement with Regeneron and Bayer to commercialize its biosimilar Aflibercept (40 mg/ml) across Europe and other global markets, following an earlier agreement covering the US and Canada.
The agreement enables Biocon Biologics to commercialize Yesafili®, its biosimilar Aflibercept, worldwide and brings an end to all related litigation. The company plans to launch Yesafili in the UK in January 2026, with rollout in other covered markets from March 2026 or earlier under certain conditions. Financial terms remain confidential.
Yesafili, a VEGF inhibitor, is used to treat multiple ophthalmic conditions, including wet age-related macular degeneration, diabetic macular oedema and retinal vein occlusion. The product has already received approvals from the European Commission and the UK’s MHRA.
Commenting on the development, Shreehas Tambe, CEO and Managing Director, Biocon Biologics, said the agreement marks a significant step in expanding the company’s ophthalmology portfolio and improving patient access globally.
Biocon Biologics had earlier secured US market entry for biosimilar Aflibercept for the second half of 2026, while the product was launched in Canada earlier this year.
